Results 51 to 60 of about 68,732 (285)

MultiMetEval: comparative and multi-objective analysis of genome-scale metabolic models [PDF]

open access: yes, 2012
Comparative metabolic modelling is emerging as a novel field, supported by the development of reliable and standardized approaches for constructing genome-scale metabolic models in high throughput.
A Freitag   +59 more
core   +6 more sources

Tissue Engineered Human Elastic Cartilage From Primary Auricular Chondrocytes for Ear Reconstruction

open access: yesAdvanced Functional Materials, EarlyView.
Despite over three decades of research, no tissue‐engineered solution for auricular reconstruction in microtia patients has reached clinical translation. The key challenge lies in generating functional elastic cartilage ex vivo. Here, we integrate synergistic cell‐biomaterial strategies to engineer auricular grafts with mechanical and histological ...
Philipp Fisch   +13 more
wiley   +1 more source

Bone Healing Around Implants in Normal and Medically Compromised Conditions: Osteoporosis and Diabetes

open access: yesAdvanced Healthcare Materials, EarlyView.
xx xx. ABSTRACT Osseointegration of orthopedic and dental implants is influenced by local and systemic factors, including their physicochemical surface properties and the patient's overall health status. Titanium and its alloys have been a longstanding standard for bone implants due to their innate biocompatibility and mechanical properties.
Dainelys Guadarrama Bello   +2 more
wiley   +1 more source

The pharmacology and function of receptors for short-chain fatty acids [PDF]

open access: yes, 2015
Despite some blockbuster G protein–coupled receptor (GPCR) drugs, only a small fraction (∼15%) of the more than 390 nonodorant GPCRs have been successfully targeted by the pharmaceutical industry.
Bolognini, Daniele   +3 more
core   +1 more source

Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine

open access: yesPharmaceutics
Recent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents.
Mohamed El-Tanani   +6 more
doaj   +1 more source

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study

open access: yesOrphanet Journal of Rare Diseases, 2019
Background Orphan medicinal products (OMPs) are intended for the diagnosis, prevention, management or treatment of rare diseases (RDs). Each RD affects only a small fraction of the population, and therefore, historically, industry hesitated to undertake ...
Mohua Chakraborty Choudhury   +1 more
doaj   +1 more source

ZNRD2 Mediated Nucleoprotein Aggregation Impairs Respiratory Syncytial Virus Replication

open access: yesAdvanced Science, EarlyView.
During RSV infection, nucleoprotein (N) forms RNA‐bound oligomers. The host protein ZNRD2 binds to these oligomers, promoting their transition into insoluble aggregates. These aggregates simultaneously sequester functional N to restrict viral production and disrupt chaperonin assembly quality control by interfering with ZNRD2's role as an adaptor ...
Haiwu Zhou   +8 more
wiley   +1 more source

Targeting the Membrane‐Embedded Rhomboid Protease GlpG: A Multimodal Strategy for Inhibitor Discovery and Mechanistic Insight

open access: yesAngewandte Chemie, EarlyView.
Created in BioRender. Bohg, C. (2026) https://BioRender.Com/ vi9hi4f. Rhomboid proteases are a mechanistically unique and evolutionarily conserved protein family. Despite their pharmacological relevance, the development of selective inhibitors has lagged behind that of soluble proteases.
Claudia Bohg   +21 more
wiley   +2 more sources

Venture philanthropy in rare disease therapy

open access: yesRare
Purpose: Rare diseases affect ∼350 million people globally, yet 94 % of those affected lack effective treatments due to funding gaps and high R&D costs.
JA Levine
doaj   +1 more source

The outcome of more than 3 decades of orphan drug development in alpha-1-antitypsin deficiency – a cross sectional analysis of the FDA Orphan Drug Product designation database

open access: yes, 2022
Abstract Introduction Alpha-1 antitrypsin deficiency (AATD, OMIM #613490) is a rare metabolic disorder affecting lungs and liver. The purpose of this study is to assess the impact of the US orphan drug act on AATD by providing a quantitative clinical-regulatory insight into the status of FDA orphan drug approvals and designations for compounds ...
Franziska C Trudzinski   +4 more
openaire   +1 more source

Home - About - Disclaimer - Privacy